Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program.

by Roland Morley, Alison Cardenas, Peter Hawkins, Yasuyo Suzuki, Virginia Paton, See-Chun Phan, Mark Merchant, Jessie Hsu, Wei Yu, Qi Xia, Daniel Koralek, Patricia Luhn, Wassim Aldairy
Published 2015-01-01

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

by Bhumsuk Keam, Jayesh Desai, Ben Markman, Michael Millward, Yoon-Koo Kang, Chia-Chi Lin, Yee Chao, Sanjeev Deva, Jong Seok Lee, Chia-Jui Yen, Michael Jameson, Ming-Mo Hou, Chang-Hsien Lu, Kun-Ming Rau, Kyung-Hun Lee, Lisa Horvath, Michael Friedlander, Paula Barlow, Chi-Yuan Wu, Liang Liang, John Wu, Virginia Paton
Published 2020-06-01